|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abbott Laboratories (NYSE: ABT ) had a busy 2017 after acquiring Alere and St. Jude Medical, earning the stock a nod of approval from a Wall Street analyst. The Analyst BMO Capital Markets' Joanne Wuensch ...
Shares of Abbott Laboratories (ABT) and Medtronic (MDT) are higher on Tuesday, following a pair of upgrades from BMO Capital Markets and Argus Research. BMO Analyst Joanne Wuensch and her team boosted their rating on the stock to Outperform from Market Perform and named it as one of their top picks for the year ahead. Wuensch writes that the move comes after its Alere and St. Jude Medical acquisitions behind it, it faces easier comparisons, and there are several new product launches ahead in 2018, making it a "year of execution." More from the note: Like everything in MedTech, stocks trade on the product pipeline, access to cash and valuation. As we exit 2017, Abbott has secured U.S. approval for its FreeStyle Libre Consumer (September 27, 2017, with increasing reimbursement throughout the year), Proclaim DRG Neurostimulator (October 6, 2017), HeartMate 3 LVAD (August 28, 2017), and MRI-conditional labelling for its Ellipse ICD (September 22, 2017).
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
Roche recently sued Pfizer to block the latter’s biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in the U.S. for Roche in 2016. The fight is unlikely to stop there for Roche, as it has a lot more at stake.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Abbott Laboratories Here are 5 ETFs with the largest exposure to ABT-US. Comparing the performance and risk of Abbott Laboratories with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Spark Therapeutics shares have plunged today, falling $27, or 37%, to $44.03 after the gene-therapy company released disappointing results for its treatment for hemophilia A at the American Society of Hematology’s annual meeting in Atlanta. The data on four patients in a phase 1/2 clinical trial showed some variability in the expression of Factor VIII, the clotting protein either missing or existing at very low levels in hemophilia A patients. It appears that Spark (ONCE) has lost the lead in developing a hemophilia A treatment to BioMarin Pharmaceutical (BMRN), a much larger biotechnology company that reported consistent levels of Factor VIII expression at the ASH conference in a phase 1/2 trial for its gene-therapy treatment.
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.
Today, the generic drug giant announced the exclusive launch of its generic Viagra (sildenafil citrate) tablets in the U.S. Viagra (generic name sildenafil) is a drug used in the treatment of erectile dysfunction, also known as impotence. Introduced by Pfizer Inc. in March 1998, Viagra has generated about $1.4 billion in the U.S., according to IMS data as of August 2017.
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
Shares of Teva Pharmaceutical Industries Ltd. rose 0.4% in morning trade Monday, after the drug maker announced the exclusive launch of its generic Viagra tablets in the U.S. The company said it will offer ...
Chairman and CEO of Abbott Laboratories (NYSE:ABT) Miles D White sold 276,886 shares of ABT on 12/06/2017 at an average price of $54.41 a share.